ELYM News and Press, Eliem Therapeutics Inc From 03/06/23

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWS...

Biotechnology company Eliem Therapeutics ( NASDAQ: ELYM ) was down ~11% after announcing reprioritization plans and ~55% layoffs in H1. The board plans to re-prioritize its pipeline to focus on the preclinical Kv7.2/3 program, development of its lead Kv7.2/3 candidate, ETX-123. Th...

Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment Implementing corporate reorganization to extend cash runway into 2027 ...

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and othe...

Eliem Therapeutics press release ( NASDAQ: ELYM ): Q3 GAAP EPS of -$0.37 beats by $0.06 . Cash, cash equivalents and short- and long-term marketable securities was $129.6 million as of September 30, 2022, including receipt of $6.2 million in tax reimbursements within t...

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorde...

Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of ongoing Phase 1 pharmacokinetic trial that are consistent with prior clinical trials Prog...

Eliem Therapeutics press release ( NASDAQ: ELYM ): Q2 GAAP EPS of -$0.56 misses by $0.09 . Cash, cash equivalents and short- and long-term marketable securities was $134.7M as of June 30, 2022, as compared to $161.4M as of December 31, 2021. With the discontinuation of...

Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage bio...

Eliem Therapeutics ELYM -25% on report to discontinue development of lead asset as mid-stage pain trial fails . Mobile Global Esports (MGAM) -14% . Senti Biosciences ( SNTI ) -10% . Celyad Oncology ( CYAD ) -11% . Eos Energy Enterprises EOSE...